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Mast cells (MCs) are key effector cells in various types of inflammatory conditions.
The MC secretory granules contain inflammatory mediators such as histamine, heparin
proteoglycan (PG), cytokines and various heparin-binding proteases, including
tryptases, chymases and carboxypeptidase A.
Previously, a mouse strain with a defect in its heparin biosynthesis was produced by
targeting the gene for NDST-2 (N-deacetylase/N-sulfotransferase-2). These mice showed
reduced levels of MC inflammatory mediators such as histamine  and various heparin-
binding proteases, including chymases, tryptases, and carboxypeptidase A. By using
this mouse strain, we found that chymase in complex with heparin PG degraded
fibronectin, suggesting a role for chymase in the regulation of connective tissue
composition. Further, we found that chymase/heparin PG complexes degraded and
thereby inactivated both thrombin and plasmin, suggesting an additional role for
chymase in regulation of extravascular coagulation and fibrinolysis. However,
although our findings implicated chymase in these processes, it was not possible to
exclude the contribution  to the observed activities by other MC components that are
influenced by the knockout of NDST-2.
Out of the different mouse chymases, mouse MC protease 4 (mMCP-4) has the most
similar tissue distribution, heparin-binding and angiotensin I-converting properties as
the only identified human chymase. Thus, mMCP-4 may be the closest homologue to
human chymase and we therefore chose to target the gene for mMCP-4. A mouse strain
with a targeted inactivation of the mMCP-4 gene was generated. This mouse strain
displayed defects in the regulation of thrombin and in fibronectin turnover,
demonstrating a key role for mMCP-4 in these processes.
To address the role of MC proteases in the activation of matrix metalloproteases
(MMPs) we used both the NDST-2 and mMCP-4 deficient mice. An analysis of
peritoneal cells and tissue extracts  from these mice revealed the presence of both pro-
MMP-9 and active enzyme (MMP-9) in WT mice, but only the proform of MMP-9 was
found in knockout mice. We also found that mMCP-4 can regulate the activation of
pro-MMP-2 in the same manner. Our findings suggest that mMCP-4 plays a critical role
in the activation of both pro-MMP-2 and pro-MMP-9 in vivo. The mMCP-4 knockout
led to the accumulation  of the fibronectin  and collagen, resulting  in fibrotic signs  in
the skin of the mMCP-4
-/- mice. Possibly,  mMCP-4-mediated activation of pro-MMP-2
and -9 may provide a link between MCs and processes that are regulated by MMPs.
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The following abbreviations are used in the text:
Ang Angiotensin
BMMC Bone marrow-derived mast cell
CD Cluster of differentiation
ChSy Chondroitin sulfate polymerase
CLP Cecal ligation and puncture
CPA Carboxypeptidase A
CS Chondroitin sulfate
CTMC Connective tissue mast cell
DPPI Dipeptidyl peptidase I
DS Dermatan sulfate
ES Embryonic stem
GAG Glycosaminoglycan
GalNAc N-acetylgalactosamine
GlcA Glucuronic acid
GlcNAc N-acetylglucosamine
GM-CSF Granulocyte-macrophage colony-stimulating factor
HDC L-histidine decarboxylase
HIV Human immunodeficiency virus
HS Heparan sulfate
IdoA Iduronic acid
Ig Immunoglobulin
IL Interleukin
LPS Lipopolysacharide
LT Leukotriene
MC Mast cell
MHC Major histocompatibility complex
MIP-1 Macrophage inflammatory protein-1
MMC Mucosal mast cell
mMCP Mouse mast cell protease
MMP Matrix metalloproteinase
MT1-MMP Membrane type 1 metalloproteinase
NDST N-deacetylase/N-sulfotransferase
NGF Nerve growth factor
PAF Platelet-activating factor
PG Prostaglandin
PMSF Phenylmethanesulfonyl fluoride
rMCP Rat mast cell protease
SCF Stem cell factor
SG Serglycin
SLPI Secretory leukocyte proteinase inhibitor
STAT Signal transducer and activator of transcription
TGF- Transforming growth factor-
TIMP Tissue inhibitor of metalloproteinase
TLR Toll-like receptor
TMT Transmembrane tryptase
TNF- Tumor necrosis factor-VEGF Vascular endothelial growth factor
WT Wild type
Xyl Xylose9
Introduction
Mast cells
There is a great variety of infectious agents in the environment that continuously
try to attack our organism. Our immune system protects us from the outer world.
Various microorganisms (bacteria, viruses, protozoa, parasites) invade our body
and induce specific immune responses. The principle components of the immune
system are lymphocytes (B cells, T cells, large granular lymphocytes, monocytes
(giving rise to macrophages), granulocytes (neutrophils, eosinophils, basophils,
mast cells (MCs)) and platelets. Each type of cell produces and secretes an array of
highly specific mediators, which are, in many cases, vitally important for our
organism.
Itching, sneezing and wheezing are typical symptoms of allergy and other
inflammatory events. The major troublemakers in these processes are MCs. These
cells were first described by Paul Ehrlich in his doctoral thesis in 1878 (Ehrlich,
1878). He detected these cells in various organs of several animal species and
introduced the term "mastzellen" meaning cells filled in their cytoplasm granules.
Development of mast cells
MCs arise from hematopoietic stem cells in the bone marrow. They circulate in
blood as precursors (Galli, 2000; Metcalfe,Baram&Mekori, 1997). Mature MCs
are not found in peripheral blood (Nakano et al., 1985) (Figure 1). These cells
completely mature in peripheral mucosal or connective tissue microenvironments
under the influence of specific growth factors (Metcalfe,Mekori&Rottem, 1995).
The latter include stem cell factor (SCF), the ligand for tyrosine kinase c-kit
receptor, interleukin (IL)-3 both in humans and rodents and nerve growth factor
(NGF) in humans only. Other mediators such as IL-4, IL-9, IL-10 can also
regulate MC differentiation (Galli, 2000; Wedemeyer&Galli, 2000).
To understand the MC  biological functions, it  is  important to clarify the
interactions of MCs with extracellular matrix components and other cells. Mast
cells adhere to extracellular matrix through the binding to the matrix components,
namely to laminin, fibronectin and vitronectin, via different integrins (Dastych et
al., 1991; Thompson,Burbelo&Metcalfe, 1990; Walsh et al., 1991). The
interaction of matrix components with MCs stimulates various processes in MCs
including protein phosphorylation, histamine release and cell motility. For
instance, membrane-bound SCF presented by fibroblasts interacts with c-kit on
MCs, facilitating the aggregation and promoting the differentiation and survival of
MCs (Adachi et  al., 1992). In addition, activated MCs aggregate with T
lymphocytes, suggesting a functional relationship between the cells
(Oh&Metcalfe, 1996).
Both MC and basophil development is associated with almost exclusive
expression of FcRI receptor on their surface. FcRI is the high affinity receptor
for immunoglobulin E (IgE) and the member of the antigen receptor superfamily10
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responsible for the connection of pathogen- or allergen-specific IgE with cellular
immunologic functions. FcRI expression occurs when the cells are still
undifferentiated and intracellular granules cannot be detected (Tkaczyk&Gilfillan,
2001). Mature MCs are characterized by condensed nuclei and the abundance of
granules in the cytoplasm.
Fig. 1. Development of mast cells from pluripotent progenirator cells. Differences in
the mast cell granule components in human and mouse mast cell subtypes.
Mast cell activation
MC can be activated in different ways. Stimulation of the MC activation, initiated
either by interaction of the antigen specific antibodies or the antigen with the
corresponding MC receptors, is referred to  as  immunologic activation.
Alternatively, the stimulation, induced by substances such as neuropeptides, basic
compounds, cytokines, and certain drugs, is called nonimmunologic activation
(Figure 2). Both immunologic and nonimmunologic stimulations produce
morphologically similar degranulation events. However, biochemical processes
preceding the degranulation are different.
FcRI
The classical MC activation during inflammatory reaction occurs through the high-
affinity receptor FcRI. FcRI is a tetrameric complex, where an extracellular 
chain binds the Fc portion of IgE, whereas a transmembrane  chain along with
disulfide-linked transmembrane  chains participate in the signal transduction.
Cross-linkage of IgE molecules bound to FcRI on MCs with allergen/ antigen
causes MC degranulation. The cascade of signal transduction pathways triggers
solubilization of the granule contents, granule swelling, membrane ruffling, fusion
of the perigranular and plasma membranes, and, finally, leading to the exocytosis
of granule content (Metzger, 1992; Turner&Kinet, 1999).11
Degranulation of the mouse MCs can be also triggered by aggregation of the
surface-expressed IgG receptors, FcRII and FcRIII. These low-affinity receptors
may regulate high-affinity IgE receptor-mediated activation (Miyajima et  al.,
1997).
Fig. 2. Schematic presentation of the different ways of mast cell activation.
Complement
Complement-dependent signals are important components of the mechanisms by
which MCs are activated during infections. MCs express multiple receptors for
the complement components  (anaphylatoxins)  C3a, C4a and C5a. These
receptors include CD11b (CR3), CD11c (CR4), which are up-regulated during
systemic mastocytosis, and C5aR (Nilsson et al., 1996). It was shown that both
C3- and C4-deficient mice demonstrated increased susceptibility to infection and
reduced MC activation (Prodeus et al., 1997).
TLR
The TLR (Toll-like receptor) family of pattern-recognition receptors has an
important role in many host defense mechanisms. Different members of the TLR
family are activated by pathogen-associated or endogenous proteins. The MC uses
selected TLRs to respond to pathogens. For example, MCs respond to
lipopolysacharide (LPS) through TLR4. In contrast, activation by peptidoglycan
from gram-positive bacteria and the yeast cell-wall component zymosan are
mediated through the TLR2 receptor (Supajatura et al., 2002).
Other activators
MC activation can be triggered by other different agents. It was demonstrated that
a number of cytokines (IL-1, IL-3) cause the release of histamine, SCF  and
macrophage inflammatory protein-1 ( MIP-1) activates the  degranulation of
MCs in vitro and in vivo (Mekori&Metcalfe, 2000).
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Dextrans and lectins appear to activate MCs through a multipotent interaction with
the cell membrane and a cross-linking of glucose receptors on the membrane.
Other compounds that can directly activate MCs include calcium ionophores,
substance P (neuropeptide), compound 48/ 80, and drugs such as morphine,
codeine and synthetic adrenocorticotropic hormone, adenosine and endothelin
(Metcalfe,Baram&Mekori, 1997).
Mast cell diversity
There is strong evidence that the morphological and histochemical diversity of
MCs and, correspondingly, MC mediator functions are controlled by tissue local
environment. Traditionally, two  MC  subtypes are distinguished in  rodents:
connective tissue MC (CTMC) localized in the sub-mucosa of the gastrointestinal
tract, in the skin and in the peritoneum (Aldenborg&Enerback, 1985), mucosal
MC (MMC), mainly found in the mucosa of the gastrointestinal system and in the
lamina propria of the respiratory tract (Enerback, 1966; Metcalfe,Baram&Mekori,
1997). Beside the localization, there are also phenotypical differences between
these MC subtypes, including size, histamine, protease and proteoglycan content
(Figure 1).
In humans MCs are classified according to the protease content. Some human
MCs (MCTC), found in connective tissues, contain tryptase, chymase, a cathepsin
G-like protease, and carboxypeptidase. Another MC subclass (MCT), found in
mucosal tissues, contain only tryptase (Irani, A.A. et al., 1986; Irani, A.M. et al.,
1989). In comparison with rodents, human MCs have the major differences in
protease content but not in histamine and proteoglycans. In rodents, MC granules
are electron-dense and homogenous. MMCs have small granules with variable
size, while CTMCs have large granules with uniform size (Amihai et al., 2001).
Ultrastructural evaluation of MCs revealed a heterogeneity of the MC-granule
structure in humans. Granules of MCT have a scroll-rich morphology, whereas
granules of MCTC have either a grating or lattice-like structure with distinct
periodicity (Weidner&Austen, 1991).
Characterization of mast cell mediators
Newly (de novo) synthesized mediators
Leukotrienes, prostaglandins and platelet-activating factor
The activation of MCs initiates de novo synthesis of lipid-derived mediators and
some cytokines. De novo synthesized MC lipid mediators are the cyclooxygenase
and lipoxygenase metabolites of arachidonic acid, which have potent inflammatory
activity. The major lipoxygenase products are leukotrienes (LTs). Sulfidopeptide
LT (LTC4) is converted to LTD4 and LTE4 after the release into extracellular
space. Leukotrienes stimulate prolonged bronchoconstriction, bronchial mucus
secretion, increased venular permeability and induce constriction of arterial and
intestinal smooth muscle (Drazen&Austen, 1987; Robinson, 2004). Human MCs
can produce LTB4 that has chemotactic activity for neutrophils, eosinophils and
enhances lysosomal enzyme release (Lewis,Austen&Soberman, 1990).13
The major cyclooxygenase product is prostaglandin (PG) D2. PGD2  acts as a
bronchoconstrictor and vasodilator and increases vascular permeability (Goetzl,
1981). PGD2 is an inhibitor of platelet aggregation, and it mediates accumulation
of neutrophils, and together with some other PGs, has antiproliferative activity
against tumor cells (Harris et al., 2002; Sasaki&Fukushima, 1994).
Platelet-activating factor (PAF) is  a potent proinflammatory phospholipid that
aggregates and degranulates platelets and leads to systemic hypotension, mediating
systemic anaphylaxis (Stafforini et al., 2003).
Cytokines, chemokines and growth factors
Both mouse and human mast cells are a source of many cytokines, chemokines
and growth factors, which are different in the two MC phenotypes. The mediators
include: IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-11, IL-13, IL-16, tumor
necrosis factor- (TNF-), granulocyte-macrophage colony-stimulating factor
(GM-CSF), SCF, vascular endothelial growth factor (VEGF), transforming growth
factor- (TGF-) and chemokines, such as MIP-1 and monocyte chemoattractant
protein-1 (Bradding et al., 1995; Galli, 2000) (more details about cytokines and
growth factors function in different processes are described below).
Interestingly, peritoneal MCs were actually the first cell type that was shown to
constitutively transcribe TNF- and contain large amounts of TNF- bioactivity
(Gordon&Galli, 1990). Both the production and storage of TNF- enables
prolonged effects of the cytokine. TNF- is important in many patho- and
physiological conditions, including neutrophil recruitment in peritonitis and
protection from endotoxic shock (Echtenacher,Mannel&Hultner, 1996; Malaviya et
al., 1996). It upregulates the expression of E-selectin and intracellular adhesion
molecule 1 on endothelial  cells, thus facilitating the trafficking of both
eosinophils and neutrophils to the inflammatory site (Gordon&Galli, 1991; Klein
et al., 1989).
De novo synthesized MC  mediators have important biological roles in
inflammation, hematopoiesis, tissue remodeling and other biological processes.
Preformed mediators
MCs contain mediators that are stored preformed in the cytoplasmic granules.
During activation they are released into the extracellular space. They include
histamine, cytokines, proteoglycans and proteases.
Histamine
Histamine is a well-known MC mediator. It is a biogenic amine, which is formed
after decarboxylation of histidine. During MC degranulation, histamine dissociates
from the proteoglycan-protein complex. Histamine is released and metabolized
within minutes, suggesting that its functional activity is present near the site of
release. The multiple biological activities of histamine are attributed to  its
activation of four receptors (H1, H2, H3, and H4). For example, the interaction of14
histamine with H1 receptors causes the contraction of airway, gastrointestinal
smooth muscle and vascular permeability (White,Slater&Kaliner, 1987).
Important information about histamine function was gained after the creation of
histamine deficient mice, by knocking out a histamine-forming enzyme (L-
histidine decarboxylase, HDC) (Ohtsu et al., 2001). Using HDC-deficient mice,
three major functions of histamine were evaluated: the significance of histamine
for gastrian action, vascular permeability and neurotransmission. There are also
newer functions of histamine, disclosed by studies on HDC-deficient mice. The
HDC-deficient mice demonstrated a delay in the development of angiogenesis. It
was also shown that histamine plays a role in the negative regulation of neutrophil
infiltration via H2 receptors in the allergic inflammation, in the suppression of the
symptoms in systemic anaphylaxis reaction. Histamine is involved in  the
accumulation of eosinophils into the airways after allergic challenge. After
stimulation of bacterial peritonitis, HDC
-/- mice were faster in the clearance of the
bacteria than wild type (WT) mice, suggesting that histamine inhibits bacterial
exclusion (Ohtsu&Watanabe, 2003).
Proteoglycans
MCs contain different types of granule proteoglycans. The proteoglycans consist
of polysaccharide chains, termed glycosaminoglycans (GAGs), which are
covalently attached to a core protein.
Heparin and chondroitin sulfate (CS) are members of this group and are
synthesized as GAG sidechains of proteoglycans. Heparin is found only inside of
secretory granules of  CTMCs, while the closely related heparan sulfate (HS)
proteoglycans are expressed and secreted by most,  if not all, mammalian cells. In
contrast to CTMCs, MMCs synthesize chondroitin-4-sulfate (CS-A), chondroitin-
4, 6-sulfate (CS-E) and also dermatan sulfate (DS) or (CS-B) (Enerback et al.,
1985; Kolset&Gallagher, 1990; Stevens, R.L. et al., 1986). In humans, both
types of MCs contain heparin and CSs (Lidholt,Eriksson&Kjellen, 1995; Stevens,
R.L. et al., 1988).
The type of GAGs may vary, whereas the core protein may be the same. The
serglycin (SG) core protein is the dominant proteoglycan found in the secretory
granule of most haemotopoietic cell types, including MCs.  Recently, SG
knockout mice were generated. It was demonstrated that SG inactivation resulted
in major defects in CTMCs, including affected morphology and ability to store
MC secretory granule proteases (Abrink,Grujic&Pejler, 2004).
In general, biosynthesis of proteoglycans occurs in the Golgi compartment, and
can be divided into three steps: chain initiation, polymerization and modification
(Lindahl,Kusche-Gullberg&Kjellen, 1998). During the chain initiation, linkage
tetrasaccharides (xylose (Xyl)-galactose (Gal)-Gal-glucuronic acid (GlcA)) are
assembled on serine residues in the core protein. The polymerization is initiated
by the work of N-acetylglucosaminotransferase (GlcNAc transferase) in the case of
heparin/HS and N-acetylgalactosaminotranferase (GalNAc transferase) in the case of
CS/DS respectively. Further, the polymerization is achieved through the activities
of chondroitin sulfate polymerase (ChSy) or heparan sulfate polymerase (EXT115
family). Heparin/HS and CS/DS chains are composed of variably sulfated
disaccharide units of iduronic acid (IdoA) IdoA1,4-GlcNAc1,4/GlcA1,4-
GlcNAc1,4 and GlcA1,3-GalNAc1,4/IdoA1,3-GalNAc1,4, respectively
(Esko&Selleck, 2002). As the chains grow, they are modified by a series of
enzymes (Figure 3).
Fig. 3. A general scheme of the synthesis of chondroitin sulfate, dermatan sulfate,
heparan sulfate and heparin glycosaminoglycans. (*) marks enzymes from knockout
mice.
The differences in composition and extent of sulfation make heparin more charged
than HS. Heparin is a unique CTMC product, suggesting specific functions for the
CTMCs, in which it plays an important role. The first and key modification
reaction in heparin/HS biosynthesis, is catalyzed by glucosaminyl N-
deacetylase/N-sulfotransferase (NDST). It removes acetyl groups from GlcNAc
residues, which are then sulfated through the N-sulfotranferase activity. There are
four isoforms of NDST (NDST-1-4) (Grobe et al., 2002). NDST-3 and -4
transcripts are predominantly expressed during embryonic development
(Aikawa&Esko, 1999; Aikawa et al., 2001). Targeting of the genes for NDST-2
and NDST-1 demonstrated that NDST-2 is essential for heparin biosynthesis while
NDST-1 is essential for heparan sulfate (Fan et al., 2000; Forsberg et al., 1999;
Humphries et al., 1999; Ringvall et al., 2000). Importantly, heparin deficient
mice (NDST-2
-/-) have defective CTMCs,  namely an altered morphology and
drastically reduced amounts of histamine and MC proteases in secretory granules.
Thus, negatively charged heparin proteoglycan is involved in the packing and
storage of positively charged proteins and histamine. Moreover, heparin
proteoglycan can modulate MC protease activity, being in complex with protease,
and facilitating the interaction with other proteins, especially with heparin-binding
proteins, without changing the actual enzymatic activity (Kolset,Prydz&Pejler,
2004). Heparin is also needed in MCs for stabilization of the tryptase tetramer and
it is required in the formation of the active tryptase tetramer (Hallgren et al., 2000;
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Hallgren,Spillmann&Pejler, 2001). The NDST-2
-/- mice were used as a model to
study the role of MC proteases in different biological processes.
Heparin has been used for many years as a potent anticoagulant, an effect mediated
by its ability to interact with anti-thrombin III via a specific pentasaccharide
sequence (Lindahl et al., 1984). However, many of the other biological properties
of heparin are unrelated to its anticoagulant activity. For example, it was shown
that heparin is able to reduce the allergen and PAF-induced eosinophil infiltration
in animals (Seeds,Hanss&Page, 1993). Heparin is also able to inhibit the
recruitment of leukocytes to tissues such as the skin and gut by the direct
inhibitory effects on the adhesion of leukocytes to vascular endothelium
(Becker,Menger&Lehr, 1994; Xie et al., 1997). It was reported that heparin
influences the fibroblast growth and collagen synthesis (Ferrao&Mason, 1993).
Further, heparin is known to act as a competitive inhibitor of enzymes of the
heparanase family, which are important in cell diapedesis and trafficking into
tissues (Vlodavsky et al., 1994). The ability of heparin to modulate different
aspects of the inflammatory response, including a role in the reduction of the
accumulation of leukocytes in the lung, allowed to use it in the treatment of
asthma and other inflammatory diseases.
Targeting of the gene for NDST-1 demonstrated a critical role of this enzyme in
HS biosynthesis. Lack of the NDST-1 results in neonatal lethality. The newborn
pups die shortly after birth due to a condition resembling respiratory distress
syndrome (Fan et al., 2000; Ringvall et al., 2000). There are a number of other
knockout animal models with targeted genes for the enzymes in heparin/HS
biosynthesis. They include EXT-1, C5 epimerase, 2-O sulfotransferase and 3-O-
sulfotransferase-1 (Bullock et al., 1998; Li et al., 2003; Lin et al., 2000; Shworak
et al., 2002). These animal models are characterized by lethal phenotypes and
abnormalities found during embryonic development, supporting the importance of
HS in the different biological processes.
The main modification steps in the CS biosynthesis include 6-O-GalNAc sulfation
(catalyzed by 6-O-GalNAc sulfotransferase) and 4-O-GalNAc sulfation (catalyzed
by 4-O-GalNAc sulfotransferase). They result in the formation of CS-A (4-O-
GalNAc sulfation) and CS-E (4-O- and 6-O-GalNAc sulfation), whereas in CS-B
biosynthesis, 2-O-IdoA sulfation additionally takes place. The targeting of the
gene for 6-O-GalNAc sulfotransferase revealed that the level of chondroitin
GalNAc-6-O-sulfate was almost undetectable, while the level of  CS-E  (with
GalNAc-4-O- and 6-O-sulfate residues) was unchanged. These results suggested
that the 6-O-sulfation reaction leading to the disulfated GalNAc residues in CS-E
is catalyzed by a separate enzyme, whereas the single sulfation of the GalNAc
residues is catalyzed by 6-O-GalNAc sulfotransferase. The deletion of the 6-O-
GalNAc sulfotransferase revealed decreased numbers of  the  naive T-lymphocytes
(Uchimura et al., 2002).
Interestingly, hyaluronic acid (hyaluronan) is a nonsulfated GAG and is not
covalently attached to core protein. Hyaluronan was found in rodent and human
skin MCs (Eggli&Graber, 1993). It was demonstrated that MC granules are a rich
source of hyaluronan, suggesting the involvment of hyaluronan in pathological17
processes such as asthma and allergy (Knutson et al., 1993; Soderberg et al.,
1989).
Neutral proteases
Another important group of preformed, cytoplasmic granule-associated mediators
is the neutral proteases. Because the amount of space in the cytoplasm of MC
limits the number of secretory granules it can retain, MCs have evolved post-
translational control mechanisms that ensure that only biologically active proteins
are targeted to the granules in defined molar ratios. Proteases in granules have a
positively charged proteoglycan-binding face on the surface of the folded protease
that resides away from the catalytic site (Sali et al., 1993). The positively charged
face on the surface of each MC protease is made up of non-contiguous residues,
which ensures that only properly folded proteases are bound to proteoglycans and
thereby targeted to the granule. It was suggested that granule proteases and SG
proteoglycans form macromolecular complexes in the trans region of the Golgi
apparatus just before they are targeted to the secretory granule.
MC granule proteases are translated as inactive zymogens, containing a
hydrophobic signal peptide followed by a propeptide that consists of 2 to 94
amino acids. The signal peptide is removed before the translated protease leaves
the endoplasmic reticulum. The site of protease activation from zymogen
precursors is not known. It may occur in a pre-secretory compartment, such as the
Golgi apparatus, avoiding premature activation of the proteases, which could cause
serious damage to the cell (Caughey, 2002).
One of the neutral proteases is carboxypeptidase A (CPA) found in CTMCs (in
both human and rodent). CPA is a Zn
2+-dependent metalloprotease with
exopeptidase activity, preferably cleaving substrates with C-terminal aromatic or
aliphatic residues. It is stored in the secretory granules of MCs,  where it forms
macromolecular complexes with proteoglycans (Goldstein et al., 1989). Granule-
bound CPA is fully active. It was suggested that the enzyme responsible for the
processing of pro-CPA might be a thiol protease since treatment of MCs with
selective thiol-protease inhibitors significantly increased amounts of pro-CPA
(Springman,Dikov&Serafin, 1995). Recent data showed that the processing of pro-
CPA to its active form requires the presence of heparin (Henningsson et al.,
2002). In addition, CPA forms a complex with another MC protease, mMCP-5,
indicating the necessity of this tandem for efficient storage of CPA and possible
involvement in various biological processes (Huang,Sali&Stevens, 1998).
Recently, it was shown that CPA together with mouse MC protease 4 (mMCP-4)
plays a key role in the formation and degradation of angiotensin II (Ang II)
(Lundequist et al., 2004).
Dipeptidyl peptidase I (DPPI), also known as cathepsin C, is a cysteine protease
of the lysosomal group, found in cytotoxic lymphocytes, neutrophils and in MCs.
DPPI plays an important role in cell growth (Thiele,McGuire&Lipsky, 1997) and
in the activation of platelet factor XIII (Lynch&Pfueller, 1988), MC proteases and
neutrophil-derived serine proteases. It also regulates the development of acute
experimental arthritis (Adkison et al., 2002) but is also essential for activation of
MC proteases. Human tryptase and chymase are synthesized as inactive zymogens18
and are then activated by removal of NH2-terminal dipeptides by DPPI
(Murakami,Karnik&Husain, 1995; Sakai,Ren&Schwartz, 1996). To determine
whether DPPI is essential for their activation in vivo, DPPI
-/- mice were created. It
was found that MCs from these mice contain normal amounts of at least two
chymases (mMCP-4 and -5), but these and other chymases are completely
inactive. Moreover, the MCs contained reduced amounts of normally processed,
active tryptase mMCP-6, suggesting that DPPI is required for the activation of
chymases, but not tryptases in mice (Wolters et al., 2001). The activation of
tryptase is a more complicated process, which requires additional processing of the
enzyme (Sakai,Ren&Schwartz, 1996).
Serine proteases
Almost one-third of all proteases can be classified as serine proteases. The serine
proteases are a class of proteolytic enzymes characterized by the presence of a
uniquely reactive serine side chain. This mechanistic class was originally
distinguished by the presence of the an aspartic acid, histidine and serine residue
(Asp-His-Ser) "charge relay" system or "catalytic triad" (Carter&Wells, 1988).
Serine proteases are endopeptidases. The potential sites of interaction of the
substrate with the enzyme are designated P, and corresponding binding sites on
the enzyme are designated S. The scissile bond (the bond to be cleaved) is the
reference point. Residues on the amino-terminal side of the scissile bond are
labeled P1, P2, P3, and so forth, indicating their positions in relation to the
scissile bond. By analogy, residues on the carboxyl side of the scissile bond are
labeled P1', P2', P3', and so forth. The corresponding enzyme sites are referred to
as S1, S2 etc. and S1', S2' etc. (Schechter, I.&Berger, 1967) (Figure 4). The
specificity of the serine proteases can be determined through recognition of the P1
side-chain. S1 specificity generally dictates the selective hydrolysis of naturally
occuring protein substrates and, therefore, is  the  most important factor
contributing to the limited proteolysis (Czapinska&Otlewski, 1999).
Fig. 4. The definition of protease-substrate interactions. The amino acid residues
toward the N-terminal end from the cleavage site are designated P1, P2, P3 etc. The
residues in the C-terminal end are designated P1', P2', P3' etc. The corresponding
binding sites on the enzyme are called S1, S2, S3…and S1', S2', S3'…respectively. The
scissile bond (in bold) is the reference point.
Chymotrypsin-like serine proteases: catalytic mechanism and specificity
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The chymotrypsin-like serine proteases catalyze the hydrolysis of proteins with
selectivity for peptide bonds on the carboxyl-side of the aromatic side chains of
Tyr, Trp, Phe, and hydrophobic residues such as Met. Trypsin-like protease and
elastase are variations of the chymotrypsin-like proteases with difference in  the
substrate specificity. In the pocket of the substrate binding site of trypsin, a Ser is
replaced by an Asp. This Asp in the pocket of trypsin can form a strong
electrostatic bond with a basic Lys or Arg side- chain of a substrate. In elastase,
the two Gly residues (as in chymotrypsin) are replaced by the much bulkier Val
and Thr, giving the possibility to form the bond with small hydrophobic residues
(Ala and Val) (Hedstrom, 2002).
In chymotrypsin and other serine proteases, highly reactive Ser
195 plays a critical
role. The first step of the hydrolysis of a peptide is acylation, the formation of a
covalent acyl-enzyme intermediate. The acyl group of the substrate is linked to the
oxygen atom of Ser
195. A proton is transferred from Ser
195 to His
57. The
positively charged His is stabilized by electrostatic interaction with negatively
charged Asp
102. After attack by the oxygen atom of the hydroxyl group of Ser
195
on the carbonyl carbon of the peptide bond, the carbon-oxygen bond of this
carbonyl group becomes a single bond, along with formation of a transient
tetrahedral intermediate. It is stabilized by hydrogen bonds between the negatively
charged carbonyl oxygen (oxyanion) and two main-chain NH groups (oxyanion
hole). In the second step, deacylation, the acyl-enzyme intermediate is hydrolyzed
by water. Finally, the acid component of the substrate is released, ready for
another round of catalysis (Carter&Wells, 1988; Kossiakoff&Spencer, 1981).
Mast cell serine proteases
The serine proteases of the MCs  are stored in secretory granules in the mature
form. The low pH of the granules helps to prevent the autolysis of the proteases
(Huang,Sali&Stevens, 1998; Lagunoff&Rickard, 1983). They are positively
charged at low pH, and form a tight complex with highly negatively charged
proteoglycan chains. This interaction results in  a  decrease of electrostatic
repulsion, allowing dense packaging of proteases in the granules (Schwartz et al.,
1981). During degranulation, the MC serine proteases are released into pH 7.0
environment. After exocytosis most MC proteases remain in macromolecular
complex with their proteoglycans. In some cases the large size of the exocytosed
protease/ proteoglycan complexes physically hinders the diffusion of the proteases
in tissues. The different MC subtypes express different serine proteases. The most
important types of serine proteases found in MC granules are chymases and
tryptases (Table 1).20
Table1. Serine proteases in the different populations of mast cells
The first member of a novel subfamily of mouse MC serine proteases, mMCP-8,
was found in MCs. A high degree of homology with mouse granzyme B in the
critical regions for substrate specificity was observed. A comparative analysis of
the amino acid sequence of mMCP-8 revealed a close relationship to cathepsin G
and T cell granzymes. MMCP-8 expression is low in normal tissues and is
completely absent in MMCs,  whereas it  is abundantly present in the lungs of
Schistosoma mansoni infected mice. It was concluded that mMCP-8 belongs to
the MC proteases but is distinct from both chymases and tryptases (Lutzelschwab
et al., 1998). MMCP-9, another member of the family of serine proteases, is
selectively expressed in uterine MCs under normal conditions. MMCP-9 was also
observed in the jejunal submucosa of Trichinella spiralis infected mice. Although
mMCP-9 exhibits a high degree of homology with other chymases, it has a
unique substrate binding cleft, suggesting the involvement of this protease in the
degradation of a distinct groups of proteins (Hunt et al., 1997)
Cathepsin G
Cathepsin G is one of the major serine proteases in neutrophils, with both tryptic
and chymotryptic specificities (Polanowska et al., 1998). It has also been found in
the human MCTC, but not in MCT. Cathepsin G plays an important role in innate
host defense against infection, confirming the similar functions for MCTC
(Schechter, N.M. et al., 1990).
Tryptases
Tryptases are a family of serine proteases with trypsin-like substrate specificity.
Tryptases are a diverse group of proteases that include  (I and II izoenzymes),
 (Ia, Ib, II and III izoenzymes) and human transmembrane tryptase/ tryptase
 (I and II izoenzymes) isoforms in humans and three tryptases (mMCP-6,
mMCP-7 and mouse transmembrane tryptase ) in mice (Caughey, 1996; Pallaoro
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et al., 1999). -tryptases are 98 to 99% identical to each other by amino acid
sequence, while -tryptases are 93% identical to  -tryptases in  amino acid
sequence (Caughey et al., 2000). As it was already mentioned, tryptases cleave
substrates at the carboxyl side of Arg and Lys residues (Hedstrom, 2002).
Tryptases are translated as zymogens with a 10-12 amino acids long N-terminal
propeptide. One of the possible candidates to activate tryptase zymogen is DPPI.
It was suggested that DPPI acts in the second phase of a two-step process. The
first step is an autocatalytic intermolecular cleavage by tryptase, which occurs
optimally at acidic pH and in the presence of heparin. The resulting product is a
monomer, which is about 50 times less active than the final tetramer. The second
step involves the removal of the remaining precursor dipeptide by DPPI, thus
allowing the mature peptide to form the active tetramer. This process also requires
heparin (Sakai,Ren&Schwartz, 1996).
The analysis of the structure of the human I-tryptase revealed that a single amino
acid residue near the active site, Asp
216, in -tryptases is replaced  by a Gly
residue in -tryptases. This fact is the reason for the low proteolytic activity of -
tryptase (Huang et al., 1998; Marquardt et al., 2002). -tryptase is not stored in
secretory granules, but instead is constitutively secreted by MCs and is the
predominant form of tryptase found in blood in both healthy subjects and those
with systemic mastocytosis under nonacute conditions (Sakai,Ren&Schwartz,
1996). During rheumatoid arthritis -tryptase appeared to be the major form in
synovial fluid (Buckley et al., 1997).
Human -tryptase is the most abundant mediator stored in MC granules and it is
the main active form of tryptase. Human -tryptase was shown to be stabilized as
an enzymatically active tetramer by association with heparin (Schwartz&Bradford,
1986). Further, it was established that it is a ring-like tetramer with the active
sites facing a central pore. Heparin chains stabilize the complex by binding to an
elongated patch of positively charged residues spanning two adjacent monomers
(Pereira et al., 1998). This unique organization explained its resistance to
macromolecular inhibitors, such as -proteinase inhibitor, 2-macroglobulin and
aprotinin (Alter et al., 1990), and explains the fairly narrow substrate specificity of
tryptase. There are just a few known macromolecular substrates for tryptase, e.g.,
fibrinogen (Schwartz et al., 1985), fibronectin (Lohi,Harvima&Keski-Oja, 1992),
but many low molecular weight peptides (vasoactive intestinal peptide, calcitonin
gene-related peptide) (Sommerhoff et al., 2000). Recent data demonstrated that -
tryptase may dissociate into active monomers with properties that are distinct from
the tetrameric counterpart (Fajardo&Pejler, 2003a). In addition, tryptase, being a
potential activator of pro-matrix metalloproteinase-3 (proMMP-3) (Gruber et al.,
1989), also possesses gelatinolytic activity (Fajardo&Pejler, 2003b). Human -
tryptase plays an important role in different biological processes. Tryptase is a
potent growth factor for epithelial cells, airway smooth muscle cells and
fibroblasts (Cairns&Walls, 1996; Gruber et al., 1997).  -tryptase  activates
protease activated receptor 2, followed by G-protein activation and intracellular
signalling (Berger et al., 2001). It is involved in  airway homeostasis,
gastrointestinal smooth muscle activity, intestinal transport, and coagulation.
Moreover, -tryptase levels in serum are elevated in most subjects with systemic
anaphylaxis of sufficient severity to cause hypertension (Schwartz et al., 1987).22
In rodents, CTMCs contain tryptase mMCP-6 (78% identity to the human -
tryptase). Studies on recombinant mMCP-6 established that formation of
enzymatically active mMCP-6 from inactive monomers requires the presence of
heparin. In the absence of heparin, mMCP-6 was present in monomeric inactive
form (Hallgren et al., 2000). The importance of heparin for tryptase activity was
confirmed by experiments in vivo, where mMCP-6 in the presence of heparin
displayed pro-inflammatory properties. Further, it  was suggested that tryptase
tetramer formation involved the bridging of tryptase monomers by heparin or other
highly sulfated polysaccharides of appropriate length.
MMCP-7 is another tryptase stored in secretory granules of CTMCs.  MMCP-7 is
not expressed in C57BL/6 mice, and thus its expression is strain dependent (Hunt
et al., 1996). In the acidic granule, mMCP-7 interacts ionically with serglycin
proteoglycan via its positively charged His residues. The proteoglycan-binding
face on the surface of mMCP-7 loses much of its positive charge when it is
exocytosed into a neutral pH environment that allows the rapid dissociation of the
tryptase from the macromolecular complex (Matsumoto, R. et al., 1995). Thus,
prolonged retention of exocytosed mMCP-6 in the extracellular matrix around
activated MCs suggested a local action, while mMCP-7, being dissociated from
heparin, easily moves from tissues and cleaves proteins located at more distant
sites. This tryptase exhibits anticoagulant activity in vivo and in vitro due to its
ability to degrade fibrinogen in the presence of a diverse array of protease
inhibitors in plasma, suggesting that fibrinogen is a physiological substrate for
mMCP-7 (Huang et al., 1997).
Transmembrane tryptase (TMT)/ tryptase  is a membrane-bound serine protease
stored in the secretory granules of human and mouse lung MCs. Mouse TMT
(mTMT) is 74% identical to human TMT (hTMT) (Wong et al., 1999). Pro--
tryptase is activated directly from its catalytically inactive zymogen form by a
tryptic protease, which will separate the propetide from the catalytic domain,
allowing it to adopt en enzymatically active conformation. Mature, active -
tryptase, unlike known tryptases, may be a two-chain protein, with part of the
propeptide remaining covalently attached via a disulfide linkage involving Cys
26.
One of the most distinctive features of TMT is the transmembrane segment located
at its COOH terminus (Caughey et al., 2000). TMT reaches the external face of
the plasma membrane when MCs are induced to degranulate. There it can cleave or
interact with proteins/ peptides residing in the extracellular matrix and on the
surface of those cells that MCs contact. TMT, therefore, functions outside of
activated MCs. TMT induces airway hyperresponsiveness in lungs by activating
an IL-13/ IL-4R/ signal transducer and activator of transcription 6  (STAT6)-
dependent pathway (Wong et al., 2002).
Chymases
MC chymases were first identified and localized in MC granules in 1959
(Benditt&Arase, 1959). As mentioned above, they possess chymotrypsin-like
substrate specificity. These proteases cleave substrates with an aromatic P1 amino
acid residue (Powers et al., 1985).23
Activation of chymase
Chymases are synthesized as inactive precursors but  are stored in  secretory
granules as active enzymes. Chymase activation in MC  granules occurs by the
removal of an acidic 2-residue propeptide by DPPI. The macromolecular complex
of inactive zymogen and heparin proteoglycan is transported in small vesicles to
the larger-sized storage granule. The negatively charged GAG successfully
competes for the positively charged face on the protease. This process causes the
liberated propeptide to be susceptible to DPPI as soon as the complex achieves the
granule. After removal of the propeptide by  DPPI, the processed chymase
undergoes a conformational change that activates the chymase. In addition, the
protease is no longer susceptible to further processing by DPPI
(Murakami,Karnik&Husain, 1995). Recently, it was suggested that after activation
heparin would promote the dissociation of chymase from DPPI (Reiling et al.,
2003) (Figure 5).
Fig. 5. The activated chymase in complex with heparin proteoglycan. After cleavage of
prochymase N-terminus by DPPI, the newly formed N-terminus of chymase is rapidly
captured by the activation groove. It is prevents further degradation of N-terminus by
DPPI and causes chymase activation.
Classification of chymases and characterization regarding angiotensin
processing
In mice, mMCP-1, -2 and -9 in MMC and mMCP-4 and -5 in CTMC were
originally identified as chymases, whereas human MCs (of the MCTC subclass)
express only a single chymase. An analysis of chymase structure by molecular
modeling revealed on the surfaces of CTMC chymases two regions with strong
positive electrostatic potentials. These regions are located far from the substrate
binding cleft. Thus, these regions may interact with heparin proteoglycan in
granules. In contrast, chymases from MMCs, with CS in granules, lack one of
these regions and have lower charge density in the other (Sali et al., 1993).
Previously, based on phylogenetic analysis, chymases were divided into two
groups:  and  chymases (Chandrasekharan et al., 1996). In mammalian MCs -
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chymases are widely expressed across species. In humans only one chymase gene,
belonging to the -family, has been identified. In contrast, rodents have been
shown to express a number of -chymase genes, including mMCP-1, -2, -4 and -9
and one -chymase, mMCP-5. Recent studies established that exchange of a
residue Gly
216 to Val in the active site of human chymase dramatically alters its
substrate specificity into being elastase-like (Solivan et al., 2002). Since all rodent
-chymases contain Val in this position, it was suggested that mMCP-5 has
elastase-like- rather than chymotrypsin-like substrate specificity (Kunori et al.,
2002). Earlier, the functional studies revealed a differencein substrate selectivity of
- and chymases regarding Ang I conversion into Ang II (Chandrasekharan et
al., 1996). Ang II is a powerful vasoconstrictor but also participates in the
inflammatory response, acting as a proinflammatory mediator (Ruiz-Ortega et al.,
2001). The Ang II is formed from Ang I (
1DRVYIHPFHL
10) by cleavage of the
Phe
8-His
9 bond. Originally, -chymases were shown to cleave the Phe
8-His
9 bond
to form Ang II whereas the -chymases cleave both the Phe
8-His
9 and Tyr
4-Ile
5
bonds degrading the Ang II (Chandrasekharan et al., 1996). Later, the involvement
of mMCP-1 in the generation of Ang II and hydrolysis at Tyr
4-Ile
5 by -chymase
(i. e., canine) was demonstrated (Saito et al., 2003). Moreover, the recent studies
revealed a cooperation between mMCP-4 and CPA  in  the formation and
degradation of Ang II and suggested a primary role for mMCP-4 in the
extravascular formation of Ang II (Lundequist et al., 2004). In addition, Lys
40
contributes to human chymase's remarkable preference for Ang II generation over
destruction (Muilenburg et al., 2002).
Inhibitors
In the cytoplasmic secretory granules of MCs, chymase is tightly bound to
proteoglycans. Upon degranulation chymase and proteoglycans remain bound to
each other. After secretion, chymase is surrounded by extracellular fluid, which
contains protease inhibitors, such as  1-antitrypsin,  2-macroglobulin,  1-
antichymotrypsin and eglin C. The concentrations of these inhibitors are likely to
increase at sites of MC activation, since histamine increases endothelial
permeability and induces leakage of plasma proteins. It was found that chymase in
complex with proteoglycans is more resistant to high molecular weight protease
inhibitors present in blood plasma, specifically to  1-antitrypsin and 2-
macroglobulin and to a lesser extent (about 50%) to 1-antichymotrypsin and
eglin C. At the same time there was no resistance  to the synthetic or
nonphysiological low molecular weight protease inhibitors, including
phenylmethanesulfonyl flluoride (PMSF), chymostatin and Soybean Bowman-
Birk protease inhibitor (Lindstedt,Lee&Kovanen,  2001). Earlier studies
demonstrated the resistance of rat mast cell chymase 1 (rMCP-1)/ heparin
proteoglycan complex to macromolecular protease inhibitors 1-antichymotrypsin
and 1-protease inhibitor, while the small synthetic serine inhibitor PMSF
inhibited chymase independently from heparin proteoglycan. Thus, proteoglycans
create a steric hindrance that limits the accessibility of the chymase to  the
inhibitors (Pejler&Berg, 1995). It is important to note that some macromolecular
inhibitors serve better as substrates for purified human skin chymase than as
inhibitors (Schechter, N.M. et al., 1989). The secretory leukocyte proteinase25
inhibitor (SLPI) is a serine proteinase inhibitor present in human mucus secretions
and tissues where MCs are located. It binds heparin. The chymase-SLPI
interactions revealed the  inhibition of chymase and resulted in the reversible
formation of their complex. Remarkably enhanced inhibition of chymase activity
was achieved in the presence of heparin (Walter,Plotnick&Schechter, 1996). This
could be explained by binding of heparin to SLPI, and that this interaction
enhances protease- inhibitor association (Faller et al., 1992). These observations
suggest that the regulation of chymases by protease inhibitors is strongly
dependent on the presence of proteoglycans.
Different approaches in the study of the biological functions of MC
proteases
The most definitive approach for characterizing the importance of a single potential
effector cell or its mediator in a biological response is to attempt to elicit the
response in animals that differ solely in having or lacking the element of interest.
MC deficient mice are one of the most important models in studies of the
physiological and pathological functions of MCs. Since MCs produce a lot of
different granule components, it is impossible to elucidate the role of certain
mediators in one or another biological process by using MC deficient mice only.
To address the in vivo functions of MC proteases and confirm previous in vitro
studies, animal models with a lack of different MC proteases are therefore needed.
In vitro, human chymase has been demonstrated to induce apoptosis of vascular
smooth muscle cells (Leskinen, M. et al., 2001) and to inhibit mitogen-induced
proliferation of human airway smooth muscle cells (Lazaar et al., 2002). Human
chymase can activate the potent inflammatory cytokine IL-1 (Mizutani et al.,
1991) and can cleave membrane bound SCF  resulting in its release from cells (de
Paulis et al., 1999). Albumin has been established as a substrate for human
chymase as well (Raymond et al., 2003). Further, the extracellular matrix-
associated latent TGF-1 was released and activated by human chymase (Taipale et
al., 1995). The intradermal injections of human chymase resulted in skin swelling
and eosinophil accumulation, suggesting a role for chymase in pathogenesis of
chronic dermatitis (Tomimori et al., 2002). NC/Nga mice develop skin lesions
similar to atopic dermatitis (Watanabe et al., 2002). Human MC chymase induces
the accumulation of neutrophils and other inflammatory cells in vivo (He&Walls,
1998a) and contributes to the increase of microvascular permeability (He&Walls,
1998b). Chymase may also play a role in heart remodeling by increasing Ang II
formation and activating MMP-9, and by regulations collagen I gene expression
(Chen et al., 2002). In vitro experiments also demonstrated the ability of mMCP-
4 to directly activate pro-MMP-9 (Coussens et al., 1999). The ability of chymase
to activate procollagenase (proMMP-1) (Saarinen et al., 1994) and prostromelysin
(proMMP-3) (Suzuki et al., 1995) suggested a  role for chymase in  tissue
remodeling. In addition, -chymase has been shown to cleave and inactivate tissue
inhibitor of metalloproteinase-1 (TIMP-1) (Frank et al., 2001). Further, human
chymase and rMCP-1 have the ability to cleave fibronectin (extracellular matrix
protein) (Leskinen, M.J. et al., 2003; Vartio,Seppa&Vaheri, 1981). In vitro
studies revealed that rMCP-1 is involved in the regulation of extravascular26
coagulation by degrading thrombin (Pejler&Karlstrom, 1993). In fact, a lot of in
vitro studies indicated the involvement of heparin proteoglycan in the cleavage of
different substrates by chymases. Chymase has the potential ability to promote
angiogenesis in hamster sponge granulomas through local chymase-dependent and
angiotensin-converting enzyme-dependent Ang II generation (Muramatsu et al.,
2000). Human chymase is also implicated in the development of bleomycin-
induced pulmonary fibrosis in mouse model (Tomimori et al., 2003). Moreover,
the development of skin fibrosis in a mouse model for scleroderma (Tsk mice) was
accompanied by upregulation of mMCP-4 (Kakizoe et al., 2001).
To address the in vivo functions of MC proteases, transgenic mouse models have
been generated. MMCP-1 is expressed constitutively, but levels increase in the
bloodstream and intestinal lumen of parasitized mice and are maximal at the time
of worm expulsion (Huntley et al., 1990). Mice lacking mMCP-1 demonstrated a
significantly delayed expulsion of the nematode Trichinella spiralis and increased
deposition of muscle larvae. This shows, for the first time, that MC proteases
have a role in the expulsion of parasites (Knight et al., 2000). The mMCP-5
deficient mice were also created. The inactivation of  mMCP-5 gene was
accompanied by reduced levels of stored CPA (Stevens et al., 1996). However,
there are no reports so far demonstrating biological consequences of the mMCP-5
disruption. Another potential model for studies of functions of CTMC proteases is
the NDST-2 deficient mouse strain, where the storage of mMCP-4, -5, -6 and
CPA was affected (Forsberg et al., 1999; Humphries et al., 1999). Finally,
mMCP-4 deficient mice were successfully created and some biological functions
of mMCP-4 have already been described (see "Present investigations").
Pathological and physiological conditions: a role for mast cells
MCs are widely distributed in the body, especially at serosal and mucosal surfaces
of the gastrointestinal tract, surface of airways and resident cells of submucosal
and dermal connective tissue. They keep a certain distance to each other and are
always prepared to repulse to invaders breaking through the first defense line.
According to their distribution it is easy to suggest that MCs play an important
role in host defense against bacterial and parasite infections by activation and
releasing different mediators (innate and acquired immunities). However, it is
important to remember that MCs  are implicated in  different pathological
conditions as well. Thus MCs possess both pathological and physiological
functions.
The most definitive approach for characterizing the importance of MCs  in  a
biological response is to attempt to elicit the response in animals that differ solely
in lacking MCs. Because of the mutation at c-kit, which encodes the receptor for a
pleiotropic growth factor that represents a major MC survival and developmental
factor, SCF, adult Kit 
W/Kit 
W-v mice virtually lack tissue MCs (Galli&Kitamura,
1987). Sl/Sl
d mice have a mutation in the gene encoding SCF.  Bone marrow from
Sl/Sl
d mice reconstitutes the MC population of Kit 
W/Kit 
W-v mice, but Sl/Sl
d mice
themselves do not respond to bone marrow transplantation because there is no
ligand for the SCF-dependent MC development (Galli,Tsai&Wershil, 1993). MC-27
deficient mice have been extensively used to characterize the role of MCs  in
numerous pathological conditions but also physiological functions of MCs.
In vivo studies employing MC-deficient mice have shown that MCs are essential
for mounting efficient innate immune responses against bacterial infections. The
MC-deficient mice are less efficient in clearing and surviving experimentally
induced enterobacterial infections (Klebsiella pneumoniae) as compared with WT
mice. It was directly correlated with fewer neutrophils at the sites of infection,
most likely as a result of lower levels of the MC-derived polymorphonuclear
granulocyte chemotactic activity induced by TNF- in these mice (Malaviya et
al., 1996). It was also found that MC-deficient mice exhibit dramatically increased
mortality after cecal ligation and puncture (CLP,  a model for acute septic
peritonitis), compared with WT mice (Echtenacher,Mannel&Hultner, 1996).
Peritoneal MCs also express complement receptors. In the CLP  model, mice
lacking complement C3 exhibited diminished degranulation of peritoneal MCs
and showed increased mortality, further suggesting a role for MCs in bacterial
infections (Prodeus et al., 1997). MCs use selected TLRs (family of pattern-
recognition receptors) to respond to pathogens. The reconstitution of Kit 
W/Kit 
W-v
mice with TLR4-deficient bone marrow-derived MCs (BMMC) during bacterial
peritonitis demonstrated increased mortality and a defective neutrophil recruitment
compared with controls. It was therefore suggested that TLR4 on MCs has a role
in MC-mediated clearance of bacteria (Supajatura et al., 2001). MCs may also be
involved in human immunodeficiency virus (HIV-1) infection. The HIV-1
glycoprotein gp120 stimulates IL-4 and IL-13 release from MCs. In addition, the
chemokine receptors CCR3 and CXCR4, co-receptors for HIV-1, are expressed by
FcRI
+ cells (Marone et al., 2001).
MCs are also important players in acquired immunity. They are capable of
phagocytizing and presenting antigens to T cells and of modulating T- and B-cell
responses such as lymphocyte growth, recruitment and Ig production. IgE
production is substantially upregulated during immune responses to infections
with intestinal parasites, where MC populations undergo considerable expansion.
Previously, it was shown that MCs participate in the expulsion of helminthes,
such as Trichinella spiralis and Stronglyoides ratti (Nawa et  al., 1985;
Oku,Itayama&Kamiya, 1984). The MCs are also capable of phagocytosis of
diverse micromolecular and particulate materials, but this ability is decreased with
the increasing maturity of the cells, indicating a close ontogenetic relationship of
MC to myeloid phagocytes (Czarnetzki, 1982). The expression of major
histocompatibility complex (MHC) class I molecules by MCs, and their ability to
express MHC class II molecules under certain circumstances (Frandji et al., 1993)
have indicated MCs as antigen presenting cells (Tedla et al., 1998).
Tissue remodeling is another process where MCs play a key role. The studies on
Kit 
W/Kit 
W-v mice demonstrated that the hair follicle cycling, which is associated
with enormous architectural changes of the skin, including proteolysis,
angiogenesis, and nerve supply rearrangement, is significantly impaired in  the
absence of MCs (Maurer et al., 1997). An analogous situation was described for
bone remodeling (Cindik et al., 2000). MCs have been shown to participate in the
physiological wound repair. They influence the wound healing process by28
increasing fibroblast migration and proliferation, which are mediated by histamine
and IL-4 (Kupietzky&Levi-Schaffer, 1996). Angiogenesis is dependent on the
balance between different angiogenic modulators and requires the  activities of
angiogenic factors, extracellular matrix proteins, adhesion receptors and proteolytic
enzymes (Pepper, 1997). MCs are a rich source of cytokines and growth factors
that induce or modulate angiogenesis. The most important of these mediators are
TNF-, IL-8, fibroblast growth factor 2,  VEGF, heparin, histamine and MC
proteases (Grutzkau et al., 1998; Norrby, 1993; Qu et al., 1998).
It has been suggested that MCs, under physiological conditions, may form a
functional unit with sensory nerves. MCs and sensory nerves may be presented as
a functional unit, having similar responses to  stimulation (degranulation),
common localization (Botchkarev et al., 1997) and activation by products from
each other (Botchkarev et al., 1995; Steinhoff et al., 2000). Finally, MCs and
sensory nerves have been suggested to cooperate in number of physiological
processes such as hair follicle cycling and development, wound healing (Gottwald
et al., 1998), stress response (Singh et al., 1999), and in the pathogenesis of
inflammatory diseases (Bienenstock et al., 1991).
Many studies have indicated a contribution of MCs in the development of
pathological conditions. In allergies, apart from the classical role in the early
phase, MCs also have an important function in its late and chronic stages through
the release of cytokines, chemokines and other mediators that can influence the
recruitment and activation of inflammatory cells such as eosinophils (De Monchy
et al., 1985), T cells, basophils (Guo et al., 1994), neutrophils (Koh et al., 1993)
and macrophages (Calhoun et al., 1993). MCs participate in the pathogenesis of
asthmatic inflammation. They are localized at the interface of the internal and
external environment within the lung where they respond to exogenous stimuli.
MC preformed mediators (tryptase, chymase, and histamine) are important in the
pathogenesis of asthmatic inflammation, whereas the newly formed mediators
cause even stronger effects. PGD2 acts as a bronchoconstrictor and vasodilator.
LTC4 is converted extracellularly into its receptor-active metabolites LTD4 and
LTE4, both potent mediators of asthma (Austen, 1995).
MCs participate in fibrotic processes. MCs are found in fibrogenic lesions in
various tissues in human diseases, such as pulmonary fibrosis (Pesci et al., 1993),
cardiovascular diseases (Matsumoto, T. et al., 2003), hepatic cirrhosis (Armbrust
et al., 1997), scleroderma and keloid (Craig,DeBlois&Schwartz, 1986). Fibrosis
also occurs during atopic dermatitis (Watanabe et al., 2002). MCs serve as a
source of proteases (tryptase and chymase) (Ruoss,Hartmann&Caughey, 1991) and
a number of cytokines (IL-4, IL-6, IL-13, TGF-, TNF-), which are mitogenic
and chemotactic for fibroblasts and stimulate the production of extracellular matrix
by fibroblasts (Gordon&Galli, 1994). Furthermore, MCs  themselves produce
components of the extracellular matrix (Thompson et al., 1991). MCs produce the
latent form of MMP-9, which is further activated by chymase (Tanaka&Matsuda,
2004). Since MMP-9 hydrolyzes basement membrane collagen types IV, V, VII,
fibronectin and elastin, this may be a mechanism, by which MC cause connective
tissue degradation under inflammatory conditions (Goetzl,Banda&Leppert, 1996).29
Angiogenesis and the production of angiogenic factors are fundamental for tumor
progression in the form of growth, invasion and metastasis. Tumors induced in
Kit 
W/Kit 
W-v display both reduced angiogenesis and ability to metastasize.
Angiogenesis is restored after local reconstitution of  MCs
(Starkey,Crowle&Taubenberger, 1988). MCs are recruited and  activated via
different factors secreted by tumor cells (Gruber,Marchese&Kew, 1995). Thus,
MCs are directly involved in tumor angiogenesis by releasing several angiogenic
factors from their secretory granules. MCs  are important in the pathogenesis of
atherosclerotic disease. Again, the secretion of pro-inflammatory cytokines and
enzymes propagate the inflammatory response and destabilize atheromatous
plaques. MCs can facilitate foam cell formation by  promoting cholesterol
accumulation (Kovanen, 1995).
In addition, MCs have been implicated in several autoimmune diseases, including,
bullous pemphigoid, experimental vasculitis and rheumatoid arthritis
(Benoist&Mathis, 2002). A study on the animal model of multiple sclerosis,
experimental allergic encephalomyelitis in Kit 
W/Kit 
W-v mice, indicated an
essential role for MCs in this neurologic inflammation (Secor et al., 2000).
In conclusion, MCs have multiple functions in many different physiological and
pathological processes, although it seems that MCs are not essential for life. They
provide important information about these processes, provoking the continuation
of the study of the role of MCs and their mediators.30
Aim and results of present investigations
Aim of the study
The general aim of this study was to investigate the biological functions of mast
cell proteases both in vitro and in vivo. The possible physiological substrates for
chymase, connective tissue type mast cell protease 4 (mMCP-4), were defined by
using heparin deficient mice (NDST-2) and mMCP-4 deficient mice. The
following aspects were investigated:
•  study of the consequences of the lack of functional heparin by analysis of
peritoneal cells from NDST-2 deficient mice and elucidation of the possible
roles of CTMC proteases (paper I)
•  study of the consequences of heparin/ MC protease deficiency for extravascular
coagulation and fibrinolysis (paper II)
•  creating of mMCP-4 deficient mice (paper III) to study the biological role and
confirm previous investigations concerning MC chymase (mMCP-4)
•  study of the importance of MCs and MC chymase in the regulation of
connective tissue homeostasis (paper IV)
Paper I. Altered processing of fibronectin in mice lacking
heparin. A role for heparin-dependent mast cell chymase in
fibronectin degradation
Previously, a mouse strain was generated with a defect in its heparin biosynthesis
by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). NDST-2 is
an enzyme involved in the initial stages of the heparin modification process. In the
absence of functional NDST-2, heparin remains as the unmodified nonsulfated
precursor. MCs from NDST-2
-/- mice showed drastically reduced levels of
inflammatory mediators, such as  histamine and various CTMC  proteases,
including tryptase mMCP-6, chymases mMCP-4, -5 and CPA. Thus, it indicated
the importance of heparin in the storage of these mediators. Finally, NDST-2
deficient mice had altered morphology of MC  granules with large "empty"
vacuoles instead of the normal electron-dense granule.
In this study peritoneal cells were harvested from normal and NDST-2
-/- mice.
After incubation of cells, SDS-PAGE analysis of cell culture media revealed the
presence of an 250 kDa protein in the medium from knockout mice, but not in
normal mice. Peptide microsequencing revealed that the identity of this protein
was fibronectin. Fibronectin is multi-functional glycoprotein and one of the
components of extracellular matrix. Fibronectin is known to play a role in various
biological processes, including cell binding, migration, matrix assembly,
embryonic development and tissue remodeling (Hynes, 1990). Moreover, altered
fibronectin processing has been found in numerous pathological conditions, such
as cancer, thrombosis and wound healing (Homandberg,  1999). Thus,
inflammatory conditions are often associated with fibronectin degradation.31
To confirm the alteration of fibronectin processing, Western blot analysis of media
from NDST-2
-/- and normal cells was performed. The results demonstrated the
presence of intact fibronectin in the NDST-2
-/- cell medium, whereas fibronectin
degradation products were clearly detected in the medium from normal mice.
Further, MC-depleted peritoneal cells were reconstituted with purified MCs,
resulting in increased fibronectin degradation in a dose-dependent manner. Hence,
the dependence on MCs was established. Experiments with inhibitors for different
classes of proteases revealed a strong inhibition of fibronectin degradation in cell
culture from normal mice by a specific inhibitor of serine proteases. Furthermore,
a macromolecular inhibitor of  chymase prevented inhibition of degradation,
suggesting that chymase, rather than tryptase, is responsible for this processing.
Addition of heparin antagonist in a similar experiment resulted in inhibition of
proteolysis in a dose-dependent fashion, indicating that this process is highly
dependent on heparin. Experiments in a purified system by using rat chymase
rMCP-1 (rat homologue to the mouse chymase mMCP-4) confirmed the increase
in the rate of chymase-catalyzed degradation of fibronectin by  heparin
proteoglycan. Finally, N-terminal sequences of fibronectin fragments, obtained by
rMCP-1 cleavage, demonstrated that all cleavage sites contain an aromatic amino
acid residue at the P1 position. These data are in agreement with the known
substrate specificities of chymotrypsin-like enzymes.
Summarizing the present study the following conclusions can be made:
•  intact fibronectin is present in the media from NDST-2
-/- mice, whereas
fibronectin degradation products are present in the media from normal mice
•  degradation of fibronectin observed in cell cultures from NDST-2
+/+ mice is
catalyzed by MC  chymase, suggesting that fibronectin may be a natural
substrate for chymase
•  degradation of fibronectin by chymase is strongly dependent on heparin.
Under physiological conditions, chymase occurs in macromolecular complex
with heparin proteoglycan. This study thus indicates that the association with
heparin proteoglycan is required for optimal chymase activity towards
fibronectin, and possibly towards other substrates
•  proteolysis of fibronectin by chymase could unleash activities of fibronectin
fragments that might potentially be important components in the regulation of
e. g. inflammatory responses.
Paper II. Regulation of extravascular  coagulation and
fibrinolysis by heparin-dependent mast cell chymase
Here we studied the consequences of heparin/ MC protease deficiency for
extravascular coagulation and fibrinolysis. Although the nature of the various
potential substrates for MC proteases is variable, it is noteworthy that several of
the known MC protease substrates belong to the coagulation system (Huang et al.,
1997; Pejler&Karlstrom, 1993). Thus, a role for MC proteases in the regulation of32
extravascular coagulation processes and the associated plasminogen activation/
plasmin system might be addressed.
In the present investigation, the NDST-2
-/- mice were used as model for studying
the biological consequences of heparin deficiency for the  macrophage
prothrombinase. Macrophages are thought to be the main cell type responsible for
initiation of coagulation at extravascular sites by expressing various coagulation
factors, including tissue factor, Factor VII, Factor X and Factor V. It was shown
that peritoneal macrophages can assemble these coagulation factors into active
Factor X-activating and prothrombinase complexes (Pejler, 1999;
Pejler,Lunderius&Tomasini-Johansson, 2000).
Addition of prothrombin to peritoneal cells, a mixture of macrophages,
lymphocytes and MCs, resulted in formation of thrombin but the accumulation of
thrombin occurred faster in the NDST-2
-/- cells than in normal controls. Further,
the generated thrombin was subsequently inactivated in  the NDST-2
+/+ cell
cultures but not in the NDST-2
-/- cells, indicating that regulation of thrombin
activity in this system is strongly heparin-dependent. Protamine, a polycationic
heparin antagonist, was added to the normal cell culture and resulted in
acceleration of the accumulation of thrombin and abolishment of subsequent
thrombin inactivation. Previous publications have shown that thrombin is  a
substrate for MC chymase (Pejler&Karlstrom, 1993; Pejler&Maccarana, 1994).
Since peritoneal MCs from heparin deficient mice completely lack MC chymase,
it was reasonable to address a role for chymase in the regulation of thrombin.
Indeed, addition of 1-antichymotrypsin to normal cells resulted in an increase in
the rate of thrombin formation and a subsequent decrease of thrombin inactivation.
In analogous experiments thrombin was added directly to NDST-2
+/+ and NDST-
2
-/- cells. Thrombin inactivation was blocked by inhibition of chymase 1-
antichymotrypsin or by protamine, suggesting the contribution of chymase and
heparin proteoglycan in the regulation of thrombin. The processing of prothrombin
was studied in peritoneal cell cultures by immunoblot analysis as well. Rapid
formation of thrombin was observed. However, generated thrombin was reduced
over time in normal cell cultures, whereas the accumulation of thrombin was
occurred in cell cultures from knockout mice.
While the extravascular coagulation was affected by  chymase and  heparin
proteoglycan at the level of inactivating thrombin, no significant differences were
found in the level of Factor Xa in both cultures. Thus, Factor Xa did not seem to
be affected by chymase-heparin complexes.
It was also reasonable to have a mechanism that would regulate the generated
thrombin to prevent the formation of excess amounts of fibrin deposits. The
extravascular plasmin/ plasminogen activator system is another potential system to
study the influence of heparin proteoglycan. Dissolution of the extravascular fibrin
deposits requires plasmin, which may be formed by action of the macrophage
urokinase plasminogen activator (uPA), provided that plasminogen is  available.
Addition of plasminogen to peritoneal cells from NDST-2
+/+ and NDST-2
-/- mice
resulted in a high rate of plasminogen activation in the cells from heparin deficient
mice compared with normal mice. The generated plasmin was, similar to33
thrombin, inactivated by MC chymase-heparin proteoglycan complexes in  the
NDST-2
+/+ but not in the NDST-2
-/- cells. Plasminogen  processing  was
investigated by immunoblot analysis. Plasminogen activation was present in both
cell cultures, but with further inactivating chymase-catalyzed cleavages occurring
mainly in the NDST-2
+/+ cultures. Further, it was established that plasminogen
processing is MC dependent. Addition of specific inhibitors to the normal cell
cultures established that plasminogen activator, especially urokinase plasminogen
activator was responsible for formation of plasmin. In addition, the rate of
inactivation of plasmin was increased upon the activation of MCs.
It was also found that protamine does not cause any major release of chymase
activity from the cells into the medium. Moreover, protamine had only a slight
direct inhibitory effect on the cell surface-associated chymase activity toward
chromogenic substrates, in agreement with the notion that protamine does not
affect the active site of chymase but rather interacts with heparin. After stimulation
of MCs, chymase-heparin proteoglycan complexes were still  located on the cell
surface as well as slightly released into the medium. Thus, the newly exocytosed
complexes tend to reassociate with the MC surface and hence be prevented from
escaping into the surrounding tissue.
Fig. 6. A model for the regulation of thrombin and plasmin activities by mast cell
chymase.
In conclusion, we found that:
•  inactivation of NDST-2, and thus of the heparin/ MC protease system, may
affect the regulation of extravascular coagulation and fibrinolysis
•   MC chymase-heparin proteoglycan complexes may modulate extravascular
coagulation and the plasminogen activator/ plasmin system by cleaving
thrombin and plasmin, respectively, into inactive fragments
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•  the heparin moiety of the chymase-heparin proteoglycan complex is necessary
to obtain optimal substrate cleavage. Binding of thrombin and plasmin are
mediated by their heparin-binding regions. Heparin acts by attracting heparin-
binding substrates, facilitating contact between them and chymase, and thus
accelerating the rate of chymase-catalyzed proteolysis of both thrombin and
plasmin (Figure 6)
•  chymase-heparin proteoglycan complexes may have the capacity to modulate
processes where the plasminogen activator/ plasmin system is involved, e. g.
tumor metastasis and wound healing.
Paper III. The chymase, mouse mast cell protease 4, constitutes
the major chymotrypsin-like activity in peritoneum and ear
tissue. A role for mouse mast cell protease 4 in thrombin
regulation and fibronectin turnover
Papers I and II suggested a crucial role for MC chymase in different biological
processes. Peritoneal MCs are known to express at least two different chymases, -
chymase mMCP-4 and -chymase mMCP-5 while in humans there is only one
chymase. However, because no reagents that specifically block either mMCP-4 or -
5 activity were available, it was not possible to distinguish whether these
processes were dependent on mMCP-4 or mMCP-5. In addition, of the known
mouse -chymases, mMCP-4 has the most similar tissue distribution to human
chymase and has also similar heparin-binding and Ang I-converting properties,
suggesting the closest relationship to  the human chymase. To confirm the
significance of chymase (most probably mMCP-4) in these processes it was
necessary to exclude an influence of other factors which are affected by absence of
the functional heparin.
We created the mMCP-4 knockout mouse strain, in order to gain further insight
into the biological function of MC chymase. A DNA fragment of the mMCP-4
gene was isolated from a genomic library. Next, we characterized the structure of
the mMCP-4 gene and identified suitable restriction sites for construction of the
target vector for homologous recombination in embryonic stem (ES) cells. The ES
cell work was performed using a standard protocol. A PCR  based strategy was
designed and used for the screening of possible positive clones. One of the
positive clones was chosen for injection into blastocysts, followed by
implantation into pseudo-pregnant mice and generation of chimeras. Further,
obtained heterozygous animals were crossed to get animals homozygous for the
mutation.
Homozygous null animals were mated and were found to be fertile. First, analysis
on two of the most CTMC-rich tissues, the peritoneum and ears, was done.
Immunoblot analysis, using specific antibodies to different CTMC proteases,
revealed full absence of immunoreactive mMCP-4 protein in  mutant mice.
Moreover, the presence of other CTMC proteases, mMCP-5, -6 and CPA was not
affected in mMCP-4
-/- mice, despite the fact that early reports demonstrated that
the lack of one MC mediator may influence the storage of others (Ohtsu et al.,35
2001; Stevens et al., 1996). Inactivation of the mMCP-4 gene did not affect the
number of MCs in the peritoneum, nor MC morphology or response to MC-
degranulating agents. Importantly, mMCP-4 showed a major contribution to the
total amount of stored chymotrypsin-like activities in tissues. At the same time,
no difference in trypsin-like or CPA  activities in peritoneum or ear tissue was
detected.
To confirm previous results, the contribution of mMCP-4 in the regulation of
thrombin activity was studied. The results showed that thrombin was rapidly
inactivated in mMCP-4
+/+ cell cultures, especially after addition of degranulating
agents, whereas the similar process was much slower in mMCP-4
-/- cell cultures.
To study the contribution of mMCP-4 in fibronectin turnover, conditioned media
from mMCP-4
+/+ and mMCP-4
-/- peritoneal cells were analyzed. The level of
intact fibronectin was much higher in medium from mMCP-4
-/- cells than in
mMCP-4
+/+. The effect was even more pronounced after stimulation of cells.
Similar experiments on older mice demonstrated that the content of intact
fibronectin in normal cultures versus knockout was much more pronounced. This
was in line with our observation that the level of surface-associated chymase
activity increases with increasing age of the animals.
To sum up the present investigation, we have shown that:
•  the inactivation of mMCP-4 did not affect the storage of other MC proteases,
and did not affect the number of MCs or MC morphology
•  mMCP-4 inactivation resulted in complete loss of chymotryptic activity in
the peritoneum and in ear tissue, indicating that mMCP-4 is the main source
of stored chymotrypsin-like protease activity at these sites
•  the mMCP-4 null cells were, in contrast to WT cells, unable to perform
inactivating cleavages of thrombin, indicating a role for mMCP-4 in
regulating the extravascular coagulation system
•  fibronectin present in connective tissues may be one of the main physiological
targets for MC chymase.
Paper IV. A key role for mast cell chymase in the activation of
pro-matrix metalloproteases-9 and -2
Numerous studies have suggested a significant role for MC chymase in various
pathophysiological events. However, it has not been possible to determine the
mechanism by which chymase influences these processes, i.e. the physiological
substrate(s) for chymase has not been identified.
MMPs hydrolyze components of the extracellular matrix. These proteases play a
central role in many biological processes, such as embryogenesis, tissue
remodeling, wound healing, angiogenesis, arthritis, cancer and tissue ulceration.
The MMPs are synthesized as inactive zymogens with an N-terminal propeptide
that needs to be removed in order to activate the latent form.36
MMP-2 and -9 or gelatinases A and B,  respectively, play an important role in
angiogenesis and tumor metastasis (Coussens et al., 2000; Hiratsuka et al., 2002).
Early in vitro studies identified a number of proteases as potential activators of
pro-MMP-9, including MMP-2, MMP-3, MMP-13 and plasmin. (Van den Steen
et al., 2002), whereas membrane type 1 MMP (MT1-MMP) and TIMP-2 are
required for pro-MMP-2 processing in vivo (Strongin et  al., 1995;
Wang,Juttermann&Soloway, 2000). Importantly, MCs are often found at the sites
where MMPs function. Moreover, MC chymase, according to previous
investigations, can directly activate pro-MMP-9 in vitro (Coussens et al., 1999;
Fang et al., 1997).
The importance of MCs in the processing of endogenous pro-MMP-9 was
investigated by culturing of normal peritoneal cells depleted of MCs or with MCs
present, followed by gelatin zymography analysis. The active form of MMP-9
appeared in the presence of MCs, while supernatants from MC-depleted cells
showed only the pro-form. Peritoneal cells from heparin deficient mice (NDST-2
-/-
mice) were used, in order to determine whether MC proteases participate in pro-
MMP-processing. These experiments showed that pro-MMP-9 processing occurred
in WT cells but not in cultures from NDST-2
-/- mice, suggesting a role for MC
proteases. To address the function of chymase in this process, mMCP-4 deficient
mice were used. Analysis of peritoneal cell cultures and extracts from ears, lungs
and hearts showed only the pro-form of MMP-9 in mMCP-4
-/- samples, whereas
both forms were found in WT samples. Gelatin zymography analysis of tissues for
MMP-2 showed the presence of pro- and active forms of MMP-2 in both WT and
mMCP-4
-/- samples. The level of active MMP-2 was higher in WT that in
mMCP-4
-/- tissues, indicating that MC chymase is important but not essential for
the activation of pro-MMP-2 in vivo. In situ gelatin zymography was used to
confirm these findings. Indeed, strong gelatinolytic activity was found in the
dermis region of ear tissue, in the vicinity of blood vessels and bronchioli in
lungs of WT, but not in chymase deficient samples.
Because MMPs have been implicated in various connective tissue remodeling
processes we next studied whether the lack of mMCP-4 and the consequent
reduction in active MMPs caused alterations in connective tissue composition.
Histochemical analysis of ear tissues revealed an increase in collagen deposition
accompanied by a significant increase in ear thickness in mMCP-4 null animals. A
similar tendency was observed in lung tissues. Immunohistochemical analysis for
fibronectin, a prominent connective tissue component, showed a markedly stronger
staining in mMCP-4 null lung- and ear tissues as compared with control,
indicating a higher degree of fibronectin deposition.
Finally, summarizing the present results we found that:
•  mMCP-4 has a central role in regulation of MMP-2 and -9 activities. Since
mMCP-4 most likely represents the functional homologue to the only human
chymase identified, we may propose a similar role for the human chymase in
the regulation of the corresponding human MMPs37
•  accumulation of connective tissue proteins in the mMCP-4
-/- tissues, which
are controlled by active MMPs, may be explained by reduced levels of active
MMPs
•  since MMP-2 and -9 have been strongly implicated in similar disorders as
those that have been linked to chymase, mMCP-4-mediated activation of pro-
MMP-2 and -9 may provide a link between MCs and processes that are
regulated by MMPs.38
Concluding remarks and outlook
MCs possess the unique ability to help the organism to fight with different outer
"enemies". Probably, the mediators that are released following MC degranulation
play important roles in the defence mechanism. Each of them has an important
function, but different mediators can be of importance, depending the particular
insult to the organism. Previously, the majority of studies on MC protease
functions were performed in vitro. Lately, a few knockout animal models for MC
mediators have been described. A major problem with some of these knockouts
(mMCP-5, CPA and HDC) is that the deletion of one MC component may
indirectly alter the levels of other MC mediators.
At the beginning of this project the aim was to look for possible functions of
CTMC proteases, focusing on the heparin deficient mice that, in turn, were almost
completely devoid of a number of CTMC proteases. After the implication of MC
chymase in the certain biological processes, the challenge was to create the
knockout animal model for the protease of our interest, mMCP-4. The obtained
transgenic animals were devoid of mMCP-4 without affecting of other MC
mediators. Such a model allowed us not only to confirm previous observations
related to chymase by indirect evidences, but will also help us to address the
potential functions of this protease in numerous patho- and physiological
processes (Figure 7).
Fig. 7. New functions for mast cell chymase revealed by in vitro and in vivo studies
In conclusion, a number of aspects can be lit up in the near future:
•  The influence of targeting of mMCP-4 on the processing of other MC granule
components, in particular those that, according to previous investigations,
might be directly or indirectly influenced by chymase (e. g., TNF-, TGF-,
SCF and IL-1)
•  The influence of targeting of mMCP-4 on the activation of other MMPs, such
as MMP-1 and MMP-3, but also the finding of new physiological substrates
CHYMASE
Extracellular matrix
remodelling
fibronectin degradation
pro-MMP-2 and –9 activation
Extravascular coagulation
and fibrinolysis
thrombin degradation
plasmin degradation
Angiogenesis
angiotensin processing39
•  Assessment of the role of mMCP-4 in different pathological conditions,
where MCs have been implicated (rheumatoid arthritis, dermatitis, asthma
model, multiple sclerosis and tumor angiogenesis)
Thus, there are still a lot of unsettled questions and enigmas as regards the
function of MC chymase. Hopefully, the results and conclusions presented in this
thesis will help to understand the function of this MC protease and inspire to
future exciting studies.40
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